Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

BioPharma Credit PLC

US BOPCF

NoneUSD
0.00(0%)

Last update at 2026-06-22T22:55:11.096127Z

Day Range

--
LowHigh

52 Week Range

0.741.00
LowHigh

Fundamentals

  • Previous Close 0.98
  • Market Cap1161.35M
  • VolumeNone
  • P/E Ratio13.38
  • Dividend Yield8.24%
  • Revenue TTM150.03M
  • Revenue Per Share TTM0.12
  • Gross Profit TTM 150.03M
  • Diluted EPS TTM0.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 129.89M 122.18M 108.45M - -
Minority interest - - - - -
Net income 129.89M 122.18M 108.45M - -
Selling general administrative - 1.97M 1.86M - -
Selling and marketing expenses - 0.18M 0.17M - -
Gross profit 114.50M 124.46M 110.49M - -
Reconciled depreciation - - - - -
Ebit - 244.36M 216.91M - 84.98M
Ebitda 129.89M 122.18M 108.45M - -
Depreciation and amortization - -122.18000M -108.45700M - -
Non operating income net other - - - - -
Operating income 129.85M 122.18M 108.45M - -
Other operating expenses 10.38M 2.28M 51.23M 0.04M 0.04M
Interest expense - - - - 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 108.45M - -
Total revenue 140.23M 124.46M 159.68M - -
Total operating expenses -15.34800M 2.28M 2.04M - -
Cost of revenue 25.73M 25.57M 25.24M - -
Total other income expense net 0.04M 122.18M -0.00700M - -
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares - - - - 84.96M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1168.42M 1199.62M 1356.73M - -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - -31.79700M 0.09M - -
Total liab 17.56M 17.94M 15.87M - -
Total stockholder equity 1150.86M 1181.68M 1340.86M - -
Deferred long term liab - - - - -
Other current liab 14.43M 16.94M 15.87M 1.95M -
Common stock 13.74M 13.74M 13.74M - 13.74M
Capital stock - - - - -
Retained earnings 36.09M 560.81M 720.00M - 742.85M
Other liab - - - - 0.56M
Good will - - - - -
Other assets - 1199.62M 48.85M - -
Cash 12.59M 5.62M 86.20M - -
Cash and equivalents - - - - -
Total current liabilities 14.43M 17.88M 15.87M - 6.34M
Current deferred revenue - - - - -
Net debt -12.58700M -5.62000M -86.20200M - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 607.12M 607.12M 607.12M - -
Property plant equipment - - - - -
Total current assets 66.19M 37.42M 155.37M - 104.72M
Long term investments - - - - -
Net tangible assets - - - - 1363.72M
Short term investments - - 48.85M - -
Net receivables 53.60M 31.80M 20.23M - 10.01M
Long term debt - - - - -
Inventory - - -0.09100M - -
Accounts payable - 0.95M - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 493.91M - 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -1162.20000M -1201.36200M - -
Deferred long term asset charges - - - - -
Non current assets total 1102.23M 1162.20M 1201.36M - -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - - -94.82100M
Change to liabilities - - - 0.00000M -2.49200M
Total cashflows from investing activities 77.48M 39.07M -1.65600M - -94.82100M
Net borrowings - - - - -
Total cash from financing activities -161.64900M -280.41500M -106.99300M - -100.15700M
Change to operating activities - - - - -
Net income 129.89M 122.18M 108.45M 0.00000M 84.96M
Change in cash 6.97M -129.43300M 14.53M - -98.56000M
Begin period cash flow 5.62M 135.05M 120.53M - -
End period cash flow 12.59M 5.62M 135.05M - -
Total cash from operating activities 91.09M 111.91M 123.18M - 96.44M
Issuance of capital stock - - - - -
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid 110.38M 174.66M 89.77M 95.74M 72.13M
Change to inventory - - - - -
Change to account receivables -21.80300M -11.48000M -0.47900M - -9.80200M
Sale purchase of stock -51.27100M -105.75300M -17.22000M - -
Other cashflows from financing activities - - -1.65600M - -
Change to netincome - - - - 23.77M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -21.23900M -10.35800M -9.22000M - -
Stock based compensation - - - - -
Other non cash items -17.55300M 0.09M 23.95M - -
Free cash flow 91.09M 111.91M 123.18M - -

Peer Comparison

Sector: Industry:

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
BOPCF
BioPharma Credit PLC		 - -% - 13.38 - 7.74 -
DOGEF
Orsted A/S		 - -% 22.01 28.82 0.66 6.50 0.07 3.88 15.58
NCRRP
NCR Corp Pref A		 - -% 1002.00 1034.35 - - -
TBB
AT&T Inc. 5.35% GLB NTS 66		 - -% 20.53 4.60 - - -
CCZ
Comcast Holdings Corp		 -0.95 1.45% 64.55 55.07 - - -

Reports Covered

Stock Research & News

View All

Profile

BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in London, the United Kingdom.

BioPharma Credit PLC

51 Lime Street, London, United Kingdom, EC3M 7DQ

Key Executives

Name Title Year Born
Mr. Pedro Gonzalez de Cosio Investment Mang. NA
Mr. Pablo Gerardo Legorreta Investment Mang. 1964
Mr. Martin G. Friedman Investment Mang. 1965
Mr. Pedro Gonzalez de Cosio Investment Manager NA
Mr. Pablo Gerardo Legorreta Investment Manager 1964
Mr. Martin G. Friedman Investment Manager 1965
Mr. Pablo Legorreta Investment Manager 1963
Mr. Martin Friedman Investment Manager 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.